Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024
Rhea-AI Summary
Assertio Holdings (Nasdaq: ASRT) announced it will release its third quarter 2024 financial results on Monday, November 11, 2024, after market close. The company will host a live webcast earnings conference call at 4:30 p.m. Eastern Time. Investors can access the webcast through Assertio's investor relations website, with connection recommended 10 minutes prior to start. For telephone access, participants can dial +1-646-307-1963 with call ID 3278948. A replay will be available approximately two hours after the call on the company's investor website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ASRT declined 4.55%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release third quarter 2024 financial results on Monday, November 11, 2024, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-646-307-1963. The call ID is 3278948.
A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.
About Assertio
Assertio is a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.
Investor Contact
Matt Kreps
Darrow Associates Investor Relations
+1-214-597-8200
mkreps@darrowir.com
FAQ
When will Assertio Holdings (ASRT) report Q3 2024 earnings?
How can I access Assertio Holdings (ASRT) Q3 2024 earnings call?
What time is Assertio Holdings (ASRT) Q3 2024 earnings call?
